DrugPatentWatch Database Preview
Litigation Details for EISAI R&D MANAGEMENT CO., LTD. v. SHILPA MEDICARE LIMITED (D.N.J. 2019)
» See Plans and Pricing
EISAI R&D MANAGEMENT CO., LTD. v. SHILPA MEDICARE LIMITED (D.N.J. 2019)
| Docket | Start Trial | Date Filed | 2019-11-07 |
| Court | District Court, D. New Jersey | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | Freda L. Wolfson |
| Jury Demand | None | Referred To | Douglas E. Arpert |
| Patents | 10,259,791; 8,029,835 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in EISAI R&D MANAGEMENT CO., LTD. v. SHILPA MEDICARE LIMITED
The small molecule drug covered by the patents cited in this case is Start Trial .
Biologic Drugs cited in EISAI R&D MANAGEMENT CO., LTD. v. SHILPA MEDICARE LIMITED
The biologic drug covered by the patents cited in this case is Start Trial .
Details for EISAI R&D MANAGEMENT CO., LTD. v. SHILPA MEDICARE LIMITED (D.N.J. 2019)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2019-11-07 | 1 | Complaint | infringement of United States Patent No. 10,259,791 (“the ’791 patent” or “the patent-in-suit”). This action…the assignee of the ’791 patent. ECL is an exclusive licensee of the ’791 patent. EML and MSD are co-exclusive… 19. The ’791 patent was duly and legally issued by the United States Patent and Trademark Office…expiration of the ’791 patent, Shilpa has infringed one or more claims of the ’791 patent under 35 U.S.C. §…expiration of the ’791 patent, Shilpa will infringe one or more claims of the ’791 patent under 35 U.S.C. | External link to document |
| 2020-05-29 | 47 | Answer to Counterclaim | MEDICARE LIMITED 8 November 2019 3:19-cv-19998 835 Patent - Abbreviated New Drug Application… 29 May 2020 PACER Document EISAI R&D MANAGEMENT CO., LTD. v. SHILPA | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
